{"id":537302,"date":"2021-09-13T08:04:14","date_gmt":"2021-09-13T12:04:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lantheus-announces-addition-of-psma-pet-imaging-agent-to-the-national-comprehensive-cancer-network-nccn-guidelines-for-prostate-cancer\/"},"modified":"2021-09-13T08:04:14","modified_gmt":"2021-09-13T12:04:14","slug":"lantheus-announces-addition-of-psma-pet-imaging-agent-to-the-national-comprehensive-cancer-network-nccn-guidelines-for-prostate-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lantheus-announces-addition-of-psma-pet-imaging-agent-to-the-national-comprehensive-cancer-network-nccn-guidelines-for-prostate-cancer\/","title":{"rendered":"Lantheus Announces Addition of PSMA PET Imaging Agent to the National Comprehensive Cancer Network\u00ae (NCCN) Guidelines for Prostate Cancer"},"content":{"rendered":"<h2>\nLantheus\u2019 product, PYLARIFY (piflufolastat F18) injection, is the first and only commercially available and FDA-approved PSMA-targeted PET imaging agent for prostate cancer<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"left\">NORTH BILLERICA, Mass., Sept.  13, 2021  (GLOBE NEWSWIRE) &#8212; Lantheus Holdings, Inc. (the \u201cCompany\u201d) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced today that prostate specific membrane antigen (PSMA) positron emission tomography (PET) imaging with piflufolastat F 18 has been included in recently updated National Comprehensive Cancer Network<sup>\u00ae<\/sup> (NCCN) Guidelines<sup>\u00ae<\/sup> for prostate cancer. The NCCN Guidelines<sup>\u00ae<\/sup> are widely recognized and used as the standard for clinical policy in oncology by clinicians and payors.<\/p>\n<p>Lantheus\u2019 product, PYLARIFY<sup>\u00ae<\/sup> (piflufolastat F 18) injection, is a radioactive diagnostic agent indicated for PET imaging of PSMA positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy and\/or with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. PYLARIFY was approved by the U.S. Food and Drug Administration (FDA) in May 2021 and remains the first and only commercially available PSMA-targeted PET imaging agent for prostate cancer.<\/p>\n<p>Prostate cancer is the second most common form of cancer affecting men in the United States and an estimated one in eight men will be diagnosed with prostate cancer in their lifetimes. The American Cancer Society estimates that in 2021, almost 250,000 new cases of prostate cancer will be diagnosed, and more than 30,000 men will die of the disease. Approximately 3.1 million men in the United States currently count themselves as prostate cancer survivors.<sup>1<\/sup><\/p>\n<p>\u201cWe are extremely pleased that the NCCN panel of prostate cancer experts, who are dedicated to high-quality, high-value, patient-centered cancer care, have added PSMA-targeted PET imaging with piflufolastat F 18 in unfavorable intermediate, high and very high risk as well as recurrent disease to the updated 2021 guidelines, for the management of prostate cancer,\u201d said Bela Denes, MD, Vice President of Medical Affairs of Lantheus. \u201cIn addition to FDA approval, inclusion in the guidelines further validates PYLARIFY\u2019s performance and utility and will raise awareness within the medical community and payors of the potential impact of this novel PSMA-targeted imaging agent in the care of men with prostate cancer.\u201d<\/p>\n<p>The NCCN<sup>\u00ae<\/sup> is a not-for-profit alliance of 31 <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1dmurt1-E9naNNLRiQxmJxpShtL18oHh6WDYhnGkH6ridUGjK02NfzILHV4GIOzJ_JpbdridbvDmFCEsRf0wciQnBEDTdZeUWWr3voJsKfuGbdC9I8Ul4uRvha2skKYF\" rel=\"nofollow noopener\" target=\"_blank\">leading cancer centers<\/a> devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. By defining and advancing high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers around the world. The NCCN Clinical Practice Guidelines in Oncology (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=anXMaEIW_Ox3rNAw9SExWPj3iIR_U7mlAfOwlkw6RUVkxupv0u_GNn687G-Qpnz6e-doReHKuFgJvCZC2060IuzszKbFtaQ8rkUX-z9fueREu24z0CgdsyWhPezypUuh\" rel=\"nofollow noopener\" target=\"_blank\">NCCN Guidelines<sup>\u00ae<\/sup><\/a>) provide transparent, evidence-based, expert consensus recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine.<\/p>\n<p>\n        <strong>About PYLARIFY<\/strong><br \/>\n        <sup><br \/>\n          <strong>\u00ae<\/strong><br \/>\n        <\/sup><br \/>\n        <strong>\u00a0(piflufolastat F 18) Injection<\/strong><br \/>\n        <br \/>PYLARIFY<sup>\u00ae<\/sup>\u00a0(piflufolastat F 18) injection (also known as\u00a0<sup>18<\/sup>F-DCFPyL or PyL) is a fluorinated small molecule PSMA-targeted PET imaging agent that enables visualization of lymph nodes, bone and soft tissue metastases to determine the presence or absence of recurrent and\/or metastatic prostate cancer. For men with prostate cancer, PYLARIFY PET combines the accuracy of PET imaging, the precision of PSMA targeting and the clarity of an F 18 radioisotope\u00a0for superior diagnostic performance. The recommended PYLARIFY dose is 333 MBq (9 mCi) with an acceptable range of 296 MBq to 370 MBq (8 mCi to 10 mCi), administered as a bolus intravenous injection.<sup>2-7<\/sup><\/p>\n<p>\n        <strong>PYLARIFY<sup>\u00ae<\/sup> (piflufolastat F 18) Injection<\/strong><br \/>\n        <br \/>\n        <strong>Indication<\/strong><br \/>\n        <br \/>PYLARIFY<sup>\u00ae<\/sup> (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:<\/p>\n<ul type=\"disc\">\n<li>with suspected metastasis who are candidates for initial definitive therapy.<\/li>\n<li>with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.<\/li>\n<\/ul>\n<p>\n        <strong>Important Safety Information<\/strong><br \/>\n        <br \/>\n        <strong>Contraindications<\/strong><br \/>\n        <br \/>None.<\/p>\n<p>\n        <strong>Warnings and Precautions<\/strong><br \/>\n        <br \/>\n        <u>Risk of Image Misinterpretation<\/u><br \/>\n        <br \/>Imaging interpretation errors can occur with PYLARIFY imaging. A negative image does not rule out the presence of prostate cancer and a positive image does not confirm the presence of prostate cancer. The performance of PYLARIFY for imaging of patients with biochemical evidence of recurrence of prostate cancer seems to be affected by serum PSA levels. The performance of PYLARIFY for imaging of metastatic pelvic lymph nodes prior to initial definitive therapy seems to be affected by risk factors such as Gleason score and tumor stage. PYLARIFY uptake is not specific for prostate cancer and may occur with other types of cancer as well as non-malignant processes and in normal tissues. Clinical correlation, which may include histopathological evaluation of the suspected prostate cancer site, is recommended.<\/p>\n<p>\n        <u>Hypersensitivity Reactions<\/u><br \/>\n        <br \/>Monitor patients for hypersensitivity reactions, particularly patients with a history of allergy to other drugs and foods. Reactions may be delayed. Always have trained staff and resuscitation equipment available.<\/p>\n<p>\n        <u>Radiation Risks<\/u><br \/>\n        <br \/>Diagnostic radiopharmaceuticals, including PYLARIFY, expose patients to radiation. Radiation exposure is associated with a dose-dependent increased risk of cancer. Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure. Advise patients to hydrate before and after administration and to void frequently after administration.<\/p>\n<p>\n        <strong>Adverse Reactions<\/strong><br \/>\n        <br \/>The most frequently reported adverse reactions were headaches, dysgeusia and fatigue, occurring at rate of \u22642% during clinical studies with PYLARIFY. In addition, a delayed hypersensitivity reaction was reported in one patient (0.2%) with a history of allergic reactions.<\/p>\n<p>\n        <strong>Drug interactions<\/strong><br \/>\n        <br \/>Androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists, may result in changes in uptake of PYLARIFY in prostate cancer. The effect of these therapies on performance of PYLARIFY PET has not been established.<\/p>\n<p>To report suspected adverse reactions for PYLARIFY, call 1-800-362-2668 or contact FDA at 1-800-FDA-1088 or\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=49Xhmc7_a3QJDMm8QALsulfliHGvgzq_o2whKJ8BBcdgZXOPIxttYKsEAstSDuiNiSMsq-m0PGaPBHj21pbsq9fZO1gagr_zRdbRNUUKwrEEZ_gJsq2i75U-AV-em6KPuk-Blfq2XRVIix7zLVQzlB71OXBcOy2GX5BwE-z0Rd12wnxUiqTPblA-MsS9uH2bitZxEhuzMeKo56rEeD4roveZpndXmJctrE1rXYRJRPQWQp7X5viKLn6lB1zXm_h3sPBXCj-_PYUKIes6lmHyLlU4vcBatf19ZfJ9C1ilZvWMfgtcNCsVpG-IVWowAQ3xXiBqVuqVQA9c02IQxWTM1uV-tg0l_em_9IAGAk-g4Hc=\" rel=\"nofollow noopener\" target=\"_blank\">www.fda.gov\/medwatch<\/a>.<\/p>\n<p>For important risk and use information about PYLARIFY Injection, please see\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2pueEo9io5xpllPeAKG7_lh7qpebF1khzojXNeBURPO01N7meMlxnPzoacUU5FAfYEkz6yLa-WvFp8qngQf3E1CZRqLL8xU1MfKjB7ReoL8sr8KLIJZVGaY4jOFQEw3BBIhZudmWvHL2u0fGNUiYg9pKimyjzs5uieHREKST8FY=\" rel=\"nofollow noopener\" target=\"_blank\">Full Prescribing information<\/a>.<\/p>\n<p>\n        <strong>About Lantheus Holdings, Inc. <\/strong><br \/>\n        <br \/>Lantheus Holdings, Inc.\u00a0is the parent company of\u00a0Lantheus Medical Imaging, Inc.,\u00a0Progenics Pharmaceuticals, Inc.\u00a0and\u00a0EXINI Diagnostics AB\u00a0and an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find Fight and Follow<sup>\u00ae<\/sup> serious medical conditions.\u00a0Lantheus\u00a0provides a broad portfolio of products, including the echocardiography agent DEFINITY<sup>\u00ae<\/sup>\u00a0Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY<sup>\u00ae<\/sup>, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; TechneLite<sup>\u00ae<\/sup>\u00a0(Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA<sup>\u00ae<\/sup>\u00a0for the treatment of certain rare neuroendocrine tumors; and RELISTOR<sup>\u00ae<\/sup>\u00a0for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc. The Company is headquartered in\u00a0North Billerica, Massachusetts\u00a0with offices in\u00a0New York,\u00a0New Jersey,\u00a0Canada\u00a0and\u00a0Sweden. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-NzuVXR9bXnAgF0dFVbGjnOUST1sV-TLMQdmbMVYrAV2k97qXln6cS1pRAk4lVh5ANGNyj3eYm3ZLkdEk366xUGaH5MBq7DhhuEqVzAkzafXZJZS3obt74-aIzFqU5npL4V_OJ-H49EGCk8393xsQcrcOy1sYYQUAPA8YDFqno19xtFe330jVB5CXbwuZph75pKtTWnf7Mqgev4_80uWYqb96DT27RZrgpg9itPvCZXYobJPi9GSPjML9v-Q-OiaWut1Xb0FDwTUA7OQFQFGnIL1NEETtKpfvPXDs1k8jEU5eUtqTKO7xNqEdvCEaVkHSoAVFdUzYsI9VLZc3XKIQw==\" rel=\"nofollow noopener\" target=\"_blank\"><strong>www.lantheus.com<\/strong><\/a>.<\/p>\n<p>\n        <strong>Safe Harbor for Forward-Looking and Cautionary Statements<\/strong><br \/>\n        <br \/>This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by their use of terms such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201cconfident,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201cwill\u201d and other similar terms. Such forward-looking statements are based upon current plans, estimates and expectations that are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements include (i) the Company\u2019s ability to successfully launch PYLARIFY as a commercial product, including (A) Lantheus\u2019 ability to obtain FDA approval for additional PET manufacturing facilities (PMFs) that could manufacture PYLARIFY, (B) the ability of those PMFs to supply PYLARIFY to customers, and (C) Lantheus\u2019 ability to sell PYLARIFY to customers; and (ii) the risks and uncertainties discussed in our filings with the Securities and Exchange Commission (including those described in the Risk Factors section in our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q), including, but not limited to those related to PYLARIFY.<\/p>\n<p>\n        <sup>1<\/sup>American Cancer Society. Facts &amp; Figures 2021. American Cancer Society. Atlanta, GA. 2021.<br \/><sup>2<\/sup>Tan N, Oyoyo U, Bavadian N, et al. PSMA-targeted radiotracers versus 18F fluciclovine for the detection of prostate cancer biochemical recurrence after definitive therapy: a systematic review and meta-analysis. Radiology. 2020;296:44-55. doi:10.1148\/radiol.2020191689<br \/><sup>3<\/sup>Mena et al. 18 F-DCFPyL PET\/CT Imaging in Patients with Biochemically Recurrent Prostate Cancer After Primary Local Therapy J Nucl Med 2020 Jun;61(6):881-889. doi: 10.2967\/jnumed.119.234799. Epub 2019 Nov 1.<br \/><sup>4<\/sup>Alipour et al. Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET? Ther Adv Med Oncol. 2019; 11: 1758835919876828.<br \/><sup>5<\/sup>Werner et al 18F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging Theranostics 2020; 10(1):1-16. doi:10.7150\/thno.37894.<br \/><sup>6<\/sup>Petersen LJ, Zacho HD. PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review. Cancer Imaging. 2020;20(1):1-8. doi:10.1186\/s40644-020-0290<br \/><sup>7<\/sup>PYLARIFY<sup>\u00ae<\/sup> [package insert]. North Billerica, MA: Progenics Pharmaceuticals, Inc., a Lantheus company<\/p>\n<p>\n        <strong>Contacts:<\/strong><br \/>\n        <br \/>Mark Kinarney<br \/>Senior Director, Investor Relations<br \/>978-671-8842<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fOUMAVY_P7x9_RZ8x2-6dKjWq1vaSNw0n9NYX6kgiQ38S84wmOaCCKDX1wh9pDQ320ydfNNLAu2oPw5bw_hYUQ==\" rel=\"nofollow noopener\" target=\"_blank\">ir@lantheus.com<\/a>\u00a0<\/p>\n<p>Melissa Downs <br \/>Director, Corporate Communications<br \/>646-975-2533<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0DAFDk7Pnk0S3OUbxLm_FfnTmBRvnF3_AZwp87jSPKDBT85P4jOYQ7S4g4vCsEHSXIrkRvEbx-KGyfQSKqkjupxgag2KV8plbQFNV6N6W4I=\" rel=\"nofollow noopener\" target=\"_blank\">media@lantheus.com<\/a><\/p>\n<p>\u00a0<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNDMyNSM0NDAwODUyIzIwMDc2OTA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NmYwYmNlNmEtNzhiMS00Nzg4LTkwZmUtY2ZlYTFkNGYxODdmLTEwMTkyNjM=\/tiny\/Lantheus-Medical-Imaging.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Lantheus\u2019 product, PYLARIFY (piflufolastat F18) injection, is the first and only commercially available and FDA-approved PSMA-targeted PET imaging agent for prostate cancer NORTH BILLERICA, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) &#8212; Lantheus Holdings, Inc. (the \u201cCompany\u201d) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced today that prostate specific membrane antigen (PSMA) positron emission tomography (PET) imaging with piflufolastat F 18 has been included in recently updated National Comprehensive Cancer Network\u00ae (NCCN) Guidelines\u00ae for prostate cancer. The NCCN Guidelines\u00ae are widely recognized and used as the standard for clinical policy in oncology by clinicians and payors. Lantheus\u2019 product, PYLARIFY\u00ae (piflufolastat &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lantheus-announces-addition-of-psma-pet-imaging-agent-to-the-national-comprehensive-cancer-network-nccn-guidelines-for-prostate-cancer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Lantheus Announces Addition of PSMA PET Imaging Agent to the National Comprehensive Cancer Network\u00ae (NCCN) Guidelines for Prostate Cancer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-537302","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Lantheus Announces Addition of PSMA PET Imaging Agent to the National Comprehensive Cancer Network\u00ae (NCCN) Guidelines for Prostate Cancer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lantheus-announces-addition-of-psma-pet-imaging-agent-to-the-national-comprehensive-cancer-network-nccn-guidelines-for-prostate-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lantheus Announces Addition of PSMA PET Imaging Agent to the National Comprehensive Cancer Network\u00ae (NCCN) Guidelines for Prostate Cancer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Lantheus\u2019 product, PYLARIFY (piflufolastat F18) injection, is the first and only commercially available and FDA-approved PSMA-targeted PET imaging agent for prostate cancer NORTH BILLERICA, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) &#8212; Lantheus Holdings, Inc. (the \u201cCompany\u201d) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced today that prostate specific membrane antigen (PSMA) positron emission tomography (PET) imaging with piflufolastat F 18 has been included in recently updated National Comprehensive Cancer Network\u00ae (NCCN) Guidelines\u00ae for prostate cancer. The NCCN Guidelines\u00ae are widely recognized and used as the standard for clinical policy in oncology by clinicians and payors. Lantheus\u2019 product, PYLARIFY\u00ae (piflufolastat &hellip; Continue reading &quot;Lantheus Announces Addition of PSMA PET Imaging Agent to the National Comprehensive Cancer Network\u00ae (NCCN) Guidelines for Prostate Cancer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lantheus-announces-addition-of-psma-pet-imaging-agent-to-the-national-comprehensive-cancer-network-nccn-guidelines-for-prostate-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-13T12:04:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNDMyNSM0NDAwODUyIzIwMDc2OTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lantheus-announces-addition-of-psma-pet-imaging-agent-to-the-national-comprehensive-cancer-network-nccn-guidelines-for-prostate-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lantheus-announces-addition-of-psma-pet-imaging-agent-to-the-national-comprehensive-cancer-network-nccn-guidelines-for-prostate-cancer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Lantheus Announces Addition of PSMA PET Imaging Agent to the National Comprehensive Cancer Network\u00ae (NCCN) Guidelines for Prostate Cancer\",\"datePublished\":\"2021-09-13T12:04:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lantheus-announces-addition-of-psma-pet-imaging-agent-to-the-national-comprehensive-cancer-network-nccn-guidelines-for-prostate-cancer\\\/\"},\"wordCount\":1678,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lantheus-announces-addition-of-psma-pet-imaging-agent-to-the-national-comprehensive-cancer-network-nccn-guidelines-for-prostate-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyNDMyNSM0NDAwODUyIzIwMDc2OTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lantheus-announces-addition-of-psma-pet-imaging-agent-to-the-national-comprehensive-cancer-network-nccn-guidelines-for-prostate-cancer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lantheus-announces-addition-of-psma-pet-imaging-agent-to-the-national-comprehensive-cancer-network-nccn-guidelines-for-prostate-cancer\\\/\",\"name\":\"Lantheus Announces Addition of PSMA PET Imaging Agent to the National Comprehensive Cancer Network\u00ae (NCCN) Guidelines for Prostate Cancer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lantheus-announces-addition-of-psma-pet-imaging-agent-to-the-national-comprehensive-cancer-network-nccn-guidelines-for-prostate-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lantheus-announces-addition-of-psma-pet-imaging-agent-to-the-national-comprehensive-cancer-network-nccn-guidelines-for-prostate-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyNDMyNSM0NDAwODUyIzIwMDc2OTA=\",\"datePublished\":\"2021-09-13T12:04:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lantheus-announces-addition-of-psma-pet-imaging-agent-to-the-national-comprehensive-cancer-network-nccn-guidelines-for-prostate-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lantheus-announces-addition-of-psma-pet-imaging-agent-to-the-national-comprehensive-cancer-network-nccn-guidelines-for-prostate-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lantheus-announces-addition-of-psma-pet-imaging-agent-to-the-national-comprehensive-cancer-network-nccn-guidelines-for-prostate-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyNDMyNSM0NDAwODUyIzIwMDc2OTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyNDMyNSM0NDAwODUyIzIwMDc2OTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lantheus-announces-addition-of-psma-pet-imaging-agent-to-the-national-comprehensive-cancer-network-nccn-guidelines-for-prostate-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lantheus Announces Addition of PSMA PET Imaging Agent to the National Comprehensive Cancer Network\u00ae (NCCN) Guidelines for Prostate Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lantheus Announces Addition of PSMA PET Imaging Agent to the National Comprehensive Cancer Network\u00ae (NCCN) Guidelines for Prostate Cancer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lantheus-announces-addition-of-psma-pet-imaging-agent-to-the-national-comprehensive-cancer-network-nccn-guidelines-for-prostate-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Lantheus Announces Addition of PSMA PET Imaging Agent to the National Comprehensive Cancer Network\u00ae (NCCN) Guidelines for Prostate Cancer - Market Newsdesk","og_description":"Lantheus\u2019 product, PYLARIFY (piflufolastat F18) injection, is the first and only commercially available and FDA-approved PSMA-targeted PET imaging agent for prostate cancer NORTH BILLERICA, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) &#8212; Lantheus Holdings, Inc. (the \u201cCompany\u201d) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced today that prostate specific membrane antigen (PSMA) positron emission tomography (PET) imaging with piflufolastat F 18 has been included in recently updated National Comprehensive Cancer Network\u00ae (NCCN) Guidelines\u00ae for prostate cancer. The NCCN Guidelines\u00ae are widely recognized and used as the standard for clinical policy in oncology by clinicians and payors. Lantheus\u2019 product, PYLARIFY\u00ae (piflufolastat &hellip; Continue reading \"Lantheus Announces Addition of PSMA PET Imaging Agent to the National Comprehensive Cancer Network\u00ae (NCCN) Guidelines for Prostate Cancer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lantheus-announces-addition-of-psma-pet-imaging-agent-to-the-national-comprehensive-cancer-network-nccn-guidelines-for-prostate-cancer\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-13T12:04:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNDMyNSM0NDAwODUyIzIwMDc2OTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lantheus-announces-addition-of-psma-pet-imaging-agent-to-the-national-comprehensive-cancer-network-nccn-guidelines-for-prostate-cancer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lantheus-announces-addition-of-psma-pet-imaging-agent-to-the-national-comprehensive-cancer-network-nccn-guidelines-for-prostate-cancer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Lantheus Announces Addition of PSMA PET Imaging Agent to the National Comprehensive Cancer Network\u00ae (NCCN) Guidelines for Prostate Cancer","datePublished":"2021-09-13T12:04:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lantheus-announces-addition-of-psma-pet-imaging-agent-to-the-national-comprehensive-cancer-network-nccn-guidelines-for-prostate-cancer\/"},"wordCount":1678,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lantheus-announces-addition-of-psma-pet-imaging-agent-to-the-national-comprehensive-cancer-network-nccn-guidelines-for-prostate-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNDMyNSM0NDAwODUyIzIwMDc2OTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lantheus-announces-addition-of-psma-pet-imaging-agent-to-the-national-comprehensive-cancer-network-nccn-guidelines-for-prostate-cancer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lantheus-announces-addition-of-psma-pet-imaging-agent-to-the-national-comprehensive-cancer-network-nccn-guidelines-for-prostate-cancer\/","name":"Lantheus Announces Addition of PSMA PET Imaging Agent to the National Comprehensive Cancer Network\u00ae (NCCN) Guidelines for Prostate Cancer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lantheus-announces-addition-of-psma-pet-imaging-agent-to-the-national-comprehensive-cancer-network-nccn-guidelines-for-prostate-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lantheus-announces-addition-of-psma-pet-imaging-agent-to-the-national-comprehensive-cancer-network-nccn-guidelines-for-prostate-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNDMyNSM0NDAwODUyIzIwMDc2OTA=","datePublished":"2021-09-13T12:04:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lantheus-announces-addition-of-psma-pet-imaging-agent-to-the-national-comprehensive-cancer-network-nccn-guidelines-for-prostate-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lantheus-announces-addition-of-psma-pet-imaging-agent-to-the-national-comprehensive-cancer-network-nccn-guidelines-for-prostate-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lantheus-announces-addition-of-psma-pet-imaging-agent-to-the-national-comprehensive-cancer-network-nccn-guidelines-for-prostate-cancer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNDMyNSM0NDAwODUyIzIwMDc2OTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNDMyNSM0NDAwODUyIzIwMDc2OTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lantheus-announces-addition-of-psma-pet-imaging-agent-to-the-national-comprehensive-cancer-network-nccn-guidelines-for-prostate-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Lantheus Announces Addition of PSMA PET Imaging Agent to the National Comprehensive Cancer Network\u00ae (NCCN) Guidelines for Prostate Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/537302","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=537302"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/537302\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=537302"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=537302"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=537302"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}